Triacylglycerol and glycogen contents in the human gastric mucosa: effect of histamine H2, muscarinic and gastrin receptors blockade.
Triacylglycerol and glycogen contents in the gastric mucosa were studied in 20 patients with duodenal ulcer before and after two-week treatment with cimetidine, pirenzepine or proglumide. Determinations of both metabolic substrates were performed in mucosal slices taken from gastric corpus and antrum during endoscopic examination: the results were expressed per mg of protein. Concentrations of triacylglycerol were significantly elevated after treatment with any of the blocking agents: in the gastric corpus by 88% after cimetidine application, 69% after pirenzepine and 102% after proglumide; in the antrum by 76, 59 and 132%, respectively. No significant changes in the mucosal contents of glycogen were observed. It is concluded that an increase in the mucosal concentration of triacylglycerol can be connected with an inhibition of the gastric acid secretion following treatment with receptor-blocking drugs.
Stasiewicz
J
J
Department of Gastroenterology, J. Sniadecki's Regional Hospital, Bialystok, Poland.
Namiot
Z
Z
Szalaj
W
W
Sobolewski
K
K
Górski
J
J
D000328:Adult; D000368:Aged; D002927:Cimetidine / Q000494:pharmacology; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism*; D006003:Glycogen / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists; D010890:Pirenzepine / Q000494:pharmacology; D011377:Proglumide / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D014280:Triglycerides / Q000378:metabolism*
D006635:Histamine H2 Antagonists; D018727:Muscarinic Antagonists; D011949:Receptors, Cholecystokinin; D014280:Triglycerides; D010890:Pirenzepine; D002927:Cimetidine; D006003:Glycogen; D011377:Proglumide